Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $2.8 million.

  • Avidity Biosciences' Other Non-Current Assets rose 3157.32% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 3157.32%. This contributed to the annual value of $2.8 million for FY2024, which is 828.57% up from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Other Non-Current Assets is $2.8 million, which was up 828.57% from $301,000 recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Other Non-Current Assets ranged from a high of $2.8 million in FY2024 and a low of $251,000 during FY2020.
  • Moreover, its 3-year median value for Other Non-Current Assets was $598,000 (2022), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Avidity Biosciences' Other Non-Current Assets plummeted by 58.17% in 2020, and later surged by 828.57% in 2024.
  • Over the past 5 years, Avidity Biosciences' Other Non-Current Assets (Yearly) stood at $251,000 in 2020, then skyrocketed by 138.65% to $599,000 in 2021, then decreased by 0.17% to $598,000 in 2022, then plummeted by 49.67% to $301,000 in 2023, then soared by 828.57% to $2.8 million in 2024.